Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
UroGen Pharma Full Year 2025 Earnings Call - Permanent J-code accelerates Zusduri launch; >$1B peak potential
UroGen framed 2025 as a launch year and 2026 as the proof point. Zusduri recorded $15.8 million in 2025 and, with a permanent J-code effective January 1, 2026, management reports clear early accelerat...
- Permanent J-code for Zusduri went into effect January 1, 2026, and management reports a visible step-up in adoption and utilization in early 2026.
- Zusduri net product revenue was $15.8 million in 2025, reflecting an early foundational launch during the miscellaneous J-code period.
- Jelmyto net product revenue was $94 million in 2025; total company revenue was $109.8 million, up 21% year-over-year from $90.4 million in 2024.
- +11 more takeaways
SQM Q4 2025 Earnings Call - Nova Andino Hits Record Lithium Volumes as Prices Inflect Higher
SQM closed 2025 with a clear operational pivot: the newly formed Nova Andino Litio JV with Codelco is running at capacity and delivered record quarterly lithium sales, while realized lithium prices in...
- SQM reported full-year 2025 revenues of $44.6 billion and net income of $588 million.
- SQM and Codelco formalized the Nova Andino Litio JV, enabling long-term lithium production from Salar de Atacama; Nova Andino is running at full capacity.
- Nova Andino sold over 66,000 metric tons of lithium in Q4 2025, more than 50% year-over-year growth and a quarterly record.
- +12 more takeaways
StealthGas Inc. Fourth Quarter 2025 Earnings Call - Debt-Free Balance Sheet, Strong Profits Despite Idle MGC
StealthGas closed 2025 with one of its strongest financial pictures in years, reporting adjusted annual net income of about $65.6 million and achieving a debt-free balance sheet after $350 million of ...
- StealthGas reported adjusted net income of $65.6 million for 2025, the second highest in company history, and adjusted quarterly net income of $13.3 million for Q4 2025.
- Q4 2025 revenues were $39.4 million, down 9.4% year on year; full-year revenues were $173.0 million, up 3.5% YoY.
- The company completed strategic deleveraging in 2025, repaying $86 million that year and $350 million since 2023, and entered 2026 with zero bank debt on the consolidated fleet.
- +14 more takeaways
Venture Global LNG Q4 2025 Earnings Call - Rapid scale-up clears path to $5.2B-$5.8B 2026 EBITDA
Venture Global used Q4 to turn promises into production. The company has quickly moved from IPO to large scale output, nearly tripling revenue and EBITDA year over year, while simultaneously building ...
- Venture Global went public in January 2025 and quickly commercialized assets, with Calcasieu Pass reaching commercial operations in April 2025.
- Q4 2025 revenue was $4.4 billion, up from $1.5 billion in Q4 2024; full year 2025 revenue was $13.8 billion versus $5.0 billion in 2024.
- Consolidated Adjusted EBITDA in Q4 2025 was $2.0 billion, a 191% increase from $688 million in Q4 2024; full year 2025 Consolidated Adjusted EBITDA was $6.3 billion.
- +17 more takeaways
Zymeworks Q4 2025 Earnings Call - Zanidatamab clinical win pushes Ziihera toward potential approval while $250M royalty note fuels buybacks and BD optionality
Zymeworks leaned into a watershed clinical moment and a creative financing move this quarter. Partners Jazz and BeiGene presented HERIZON-GEA-01 data showing zanidatamab combinations produced a median...
- HERIZON-GEA-01 data presented by partners Jazz and BeiGene showed zanidatamab plus chemotherapy, with or without a checkpoint inhibitor, achieved median PFS > 1 year and median overall survival > 2 years in first-line HER2-positive metastatic or locally advanced GEA.
- Jazz expects to submit a supplemental BLA under the FDA Real-Time Oncology Review program in Q1 2026 and anticipates potential approval and launch of zanidatamab (Ziihera) in GEA in H2 2026, subject to FDA review; an additional interim median OS analysis is expected by mid-2026.
- Zanidatamab has Breakthrough Therapy designation for HER2-positive GEA and the HERIZON-GEA-01 benefit was consistent across clinically relevant subgroups, irrespective of PD-L1 exploratory results.
- +12 more takeaways
AAON, Inc. Q4 2025 Earnings Call - BASX Demand Surges to $1.3B Backlog, Margins Hit by Ramping and ERP Headwinds
AAON closed 2025 on clear top-line strength, driven by an accelerating BASX data center business and a resilient AAON branded commercial segment. BASX bookings and backlog exploded, but the company pa...
- BASX momentum is real: full-year BASX branded sales rose 143% to $548 million, and BASX backlog reached $1.3 billion, up 141% year-over-year and 45% sequentially.
- BASX book-to-bill was 2.4 for 2025, signaling strong order intake versus current production capacity.
- Q4 net sales were $424.2 million, up 42.5% year-over-year; BASX Q4 sales grew 109.1% to $106.1 million, AAON branded Q4 sales rose 9.5%.
- +12 more takeaways
TGS Q4 2025 Earnings Call - Bond-Funded Buildout Puts Perito Moreno Expansion and $2.9bn NGL Project on Fast Track
TGS reported a softer Q4 2025 profit but materially stronger liquidity after a $500 million, 10-year bond that closed oversubscribed and lifted cash to ARS 1,808 billion. The quarter shows two stories...
- TGS issued a $500 million, 10-year bond at an 8% yield in November, the deal was oversubscribed with an order book of $1.3 billion.
- Proceeds from the bond are financing roughly $780 million of CapEx tied to the Perito Moreno pipeline expansion plus final regulated pipeline tranches adding a combined 26 million cubic meters per day of capacity.
- Company cash rose by ARS 864 billion in Q4 to ARS 1,808 billion (about $1.25 billion at the official rate), driven mainly by the bond proceeds.
- +12 more takeaways
Turning Point Brands Fourth Quarter 2025 Earnings Call - White pouch surge forces front-loaded investment
Turning Point Brands closed 2025 on a clear inflection point, driven by a rapid ramp of Modern Oral white nicotine pouches. Consolidated revenue rose 29% to $121 million, with Modern Oral net revenue ...
- Revenue up 29% year-over-year to $121.0 million in Q4 2025, driven primarily by Modern Oral (white pouch) growth.
- Modern Oral net revenue was $41.3 million in Q4, a 266% year-over-year increase; Modern Oral gross sales rose 337% year-over-year.
- Company is initiating 2026 Modern Oral guidance: gross sales $220 million to $240 million, net sales $180 million to $190 million.
- +12 more takeaways
Xeris Biopharma Q4 2025 Earnings Call - Financial self-sustainability and 30%+ revenue growth guide for 2026
Xeris closed 2025 with a clean break from the financing treadmill, reporting full-year revenue of $291.8 million, adjusted EBITDA of $59.4 million and net income for the year. Management calls 2025 tr...
- Full-year 2025 revenue was $291.8 million, up 44% year-over-year; Q4 revenue was $85.8 million, up 43% y/y.
- Xeris reported adjusted EBITDA of $59.4 million for 2025 and delivered net income on a full-year basis for the first time.
- Management says Xeris achieved financial self-sustainability, enabling internal funding for the pipeline and commercial expansion.
- +15 more takeaways
Norwegian Cruise Line Holdings Q4 2025 Earnings Call - New CEO flags execution failures, trims 2026 yield outlook to flat
John Chidsey, who joined the board last year and became CEO in the last two weeks, laid out a blunt diagnosis: strategy is sound, execution is not. Q4 and full-year 2025 results showed healthy margin ...
- New CEO John Chidsey has been on the job only a few weeks, and his top priorities are fixing execution, driving accountability, reducing leverage, and improving return on invested capital.
- Q4 2025 net yields grew 3.8%, full-year 2025 net yields rose 2.4% versus prior year.
- Q4 Adjusted EBITDA was $564 million, full-year Adjusted EBITDA was $2.73 billion, up 11% year-over-year; Adjusted Operational EBITDA margin improved to 37.1% (+160 bps).
- +12 more takeaways